仟源医药：子公司获得药品注册证书及化学原料药上市申请批准通知书

Core Viewpoint - The approval of the drug Eivocase tablets by the National Medical Products Administration is expected to enhance the company's product portfolio and market competitiveness, although future sales remain uncertain [1] Group 1: Regulatory Approvals - The subsidiary Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. received the drug registration certificate for Eivocase tablets [1] - The subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. received the approval notice for the listing application of Eivocase as a chemical raw material drug [1] Group 2: Product Indication and Market Impact - Eivocase tablets are indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis and are classified as a Category B product in the national medical insurance catalog [1] - The approval of this drug is anticipated to enrich the company's product structure and enhance its market competitiveness [1]